Silagene Overview

  • Founded
  • 2008
  • Status
  • Private
  • Latest Deal Type
  • Angel
  • Latest Deal Amount
  • $75K
Latest Deal Amount
  • Investors
  • 2

Silagene General Information


Developer of U1 adaptor technology designed to facilitate the creation of U1 adaptors with therapeutic potential The company's technology overcomes the limitations of gene silencing technologies, enabling doctors to to treat patients with various types of cancers.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Primary Industry
Primary Office
  • 1 Ilene Court Suite 9
  • Hillsborough, NJ 08844
  • United States
+1 (908) 000-0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Silagene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Angel (individual) 04-May-2020 $75K 0000 Completed Startup
1. Grant 01-Jan-2010 00000 Completed Startup
To view Silagene’s complete valuation and funding history, request access »

Silagene Executive Team (2)

Name Title Board Seat Contact Info
Samuel Gunderson Ph.D Co-Founder, Chief Executive Officer and President
Rafal Goraczniak Co-Founder
To view Silagene’s complete executive team members history, request access »

Silagene Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Affinity Asset Advisors Other Minority 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view Silagene’s complete investors history, request access »